Clinical Trial: Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: SSRIs and Self-harm in Borderline Personality Disorder
Brief Summary: The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.
Detailed Summary:
Sponsor: University of Chicago
Current Primary Outcome: self-harm ideation [ Time Frame: pretreatment to 1-week post treatment ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Depressive symptoms [ Time Frame: pre-treatment to 1 week post-treatment ]
Original Secondary Outcome: Same as current
Information By: University of Chicago
Dates:
Date Received: April 12, 2010
Date Started: September 2010
Date Completion:
Last Updated: April 7, 2015
Last Verified: April 2015